Charles Weijer is Professor and Canada Research Chair in Bioethics at the Rotman Institute of Philosophy at Western University in London, Canada. He is the leading expert on the ethics of randomized controlled trials. In 2008, Charles founded the Rotman Institute of Philosophy, which is dedicated to fostering collaboration between the humanities and the sciences, and served as the Institute’s first director. In 2014, he received Western’s Hellmuth Prize for Achievement in Research, and, in 2016, he was elected to the Royal Society of Canada
Dr. Frank Naus is the Chief Operating Officer of Allphase Clinical Research Inc., a Canadian CRO headquartered in Ottawa, Ontario. Frank earned his Doctorate in Business Administration from Walden University and has an MBA from Wilfrid Laurier University and MSc and BSc degrees in Applied Health Sciences from the University of Waterloo. Frank started his career in the pharmaceutical and clinical research industry. Prior to joining Allphase, he was Vice President Research at Hamilton Health Sciences.
Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO), the industry voice for the life sciences sector in Ontario. Jason obtained his PhD in Chemistry from the University of Massachusetts and his undergraduate degree from the University of Waterloo. Following graduate school, Jason returned to Ontario and worked in the pharmaceutical industry as a research scientist developing scalable manufacturing processes of active pharmaceutical ingredients.
Dr. Anne Mullin works with leading decision-makers across the health and life sciences sector to amplify the impact of biomedical discoveries and healthcare innovations on the health and wellbeing of populations in both developed and developing countries.
Anne’s collaborative approach to working with clients and rich academic track record in the study of infectious disease have supported the sustainability and success of numerous international product development consortia, allowed both industry and academic partners to manage risk of high-impact clinical trials, and helped clients from industry, academia and the not-for-profit sector attract capital, establish partnerships and drive innovation. Having led engagements in North America, Europe, Southeast Asia and Africa, Anne’s client base spans the globe.
Monica Taljaard is a Senior Scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute (OHRI) and Associate Professor in the School of Epidemiology and Public Health at the University of Ottawa. She received her PhD degree in Epidemiology and Biostatistics at Western University in 2006. Her main research interests are in the design, analysis and ethics of cluster randomized trials. As a methodologist with the Ottawa Methods Centre, she works with clinicians and researchers from a variety of disciplines and medical specialties in the design and analysis of cluster randomized trials, standard clinical trials, and observational studies. She supervises MSc and PhD students in Epidemiology and teaches Biostatistics courses at the University of Ottawa.
Patrick Clifford is currently the Director of Research and Innovation, at the Research Institute of Southlake Regional Health Centre in Newmarket Ontario and CreateIT Now the Southlake owned and operated on campus health innovation centre. Patrick’s responsibilities include 1/oversight of research operations and infrastructure (including the REB) and 2/ advancing innovation and commercialization activities along with culture building, through strategic collaborations with industry, academia, funders and other key partners. Currently Patrick is charged with leading the development and implementation of Southlake’s research agenda and advancing the innovation and commercialization strategy which includes growing partnerships and collaborations with private sector ventures wishing to test and/or validate wide ranging health focused technologies with Southlake clinicians in an acute care, large community hospital environment. Patrick is also engaged in Southlake’s health sector leadership role in innovative, outcome based, procurement practices. Patrick brings 32 years of health care experience in acute care to his current role. He holds an MSW, a BA, BSW and BEd. and continues to practice as a clinician on a periodic basis in an emergency mental health setting.
Dr Carole Légaré completed her medical training at the University of Ottawa, and her postgraduate pharmacoepidemiology and pharmacovigilance training at the London School of Hygiene and Tropical Medicine in the UK. After gaining experience in clinical practice and public health, she joined Health Canada in 2002 where she initially worked in pharmacovigilance. She also worked as a senior medical advisor for the Centre for Biologics Evaluation during the H1N1 influenza pandemic. In 2013, she joined the Therapeutic Products Directorate as the Director of the Office of Clinical Trials, where she oversees all activities related to the approval and pharmacovigilance of clinical trials involving pharmaceuticals. She is currently a member of the ICH E8 working group on General Considerations for Clinical Studies.
Michael Israels is the Chief Financial Officer of the Centre for Commercialization of Regenerative Medicine (CCRM). Prior to joining CCRM, Michael was a Management Consultant at Ernst & Young LLP, President of BEST Funds, a Toronto-based venture capital firm, and CEO Of Convexus Managed Services Inc., a start-up investment fund administration company. As CFO, Michael is responsible for overseeing finance, administrative, facility & IT activities, the creation and support of start-up regenerative medicine companies, risk management activities, sourcing of risk capital, corporate development supporting CCRM’s growth strategy, and development of investment funding vehicles.
Dr Mark Clemons graduated from the University of Newcastle upon Tyne, U.K. (B.Med.Sci; MB BS). He completed his post-doctoral training in internal medicine and medical oncology at the Hammersmith Hospital, London; Christie Hospital, Manchester (MSc, Oncology; MD, Oncology) and at the Princess Margaret Hospital, Toronto. He is a Clinical Investigator at the Ottawa Hospital Research Institute (Cancer Therapeutics Program), staff medical oncologist (Ottawa Hospital Cancer Centre) and Professor of Medicine (University of Ottawa). He is the recipient of multiple peer-reveiwed research grants and is widely published in the field of breast cancer management. His publications also reflect eclectic topics such as; retirement planning, excessive oncologist travel, oncologist quality of life and issues such as preventing spam. His current research vision is to remove many of the barriers that lead the development of multiple standard of care therapies with very little data to actually show which treatment is best in the real world setting.
Dr. Andy J. Smith is the President and Chief Executive Officer of Sunnybrook Health Sciences Centre in Toronto, Ontario. In addition, he is a Professor of Surgery at the University of Toronto. He completed medical school, including a Masters of Science, and General Surgery residency at the University of Toronto. He also completed a Surgical Oncology Fellowship at Memorial Sloan – Kettering Cancer Center in New York. Upon returning to Canada, he established himself as a leader in the management of colorectal cancer. He has served as Head of the Division of General Surgery at Sunnybrook, Chair of the Division of General Surgery at the University of Toronto and Chief of the Odette Cancer Program and Regional Vice President for Cancer Care Ontario. Most recently, Dr. Smith has served Sunnybrook as its Executive Vice President, Chief Medical Executive.